Literature DB >> 657588

Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release.

E Fernandez-Cruz, P Escartin, A Bootello, M Kreisler, J M Segovia de Arana.   

Abstract

We have used a cytoplasmic enzyme system in the study of the in vitro cytotoxic activity of human peripheral blood leucocytes against isolated liver cells in patients with chronic liver diseases. Lymphocytes from primary biliary cirrhosis and chronic active liver disease patients were shown to have an in vitro capacity to induce a cytolitic effect on isolated hepatocytes, as demonstrated by the enhanced release of lactate dehydrogenase (LDH), a cytoplasmic marker enzyme. No significant LDH release was seen with control lymphocytes of normal persons or with lymphocytes from patients with alcoholic cirrhosis. Our results corroborate, in a different assay system, by a simple, reproducible and different method, that lymphocyte-mediated liver cell damage "in vitro" occurs in both primary biliary cirrhosis and chronic active liver disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657588      PMCID: PMC1541248     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  The inhibition of phagocytosis and facilitation of exocytosis in rabbit polymorphonuclear leukocytes by cytochalasin B.

Authors:  P Davies; R I Fox; M Polyzonis; A C Allison; A D Haswell
Journal:  Lab Invest       Date:  1973-01       Impact factor: 5.662

2.  Lymphocyte transformation and persistent Australia antigen.

Authors:  A I Sutnick; W T London; B S Blumberg
Journal:  Lancet       Date:  1973-05-19       Impact factor: 79.321

3.  Release of basic proteins and lysosomal enzymes from neutrophil leukocytes of the rabbit.

Authors:  N S Ranadive; A N Sajnani; K Alimurka; H Z Movat
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

4.  Thymus-dependent lymphocyte function in patients with hepatitis-associated antigen.

Authors:  V Giustino; F J Dudley; S Sherlock
Journal:  Lancet       Date:  1972-10-21       Impact factor: 79.321

5.  Cellular immunity and hepatitis-associated, Australia antigen liver disease.

Authors:  F J Dudley; R A Fox; S Sherlock
Journal:  Lancet       Date:  1972-04-01       Impact factor: 79.321

6.  Impaired delayed hypersensitivity in primary biliary cirrhosis.

Authors:  S Sherlock; R A Fox; D G James; P J Scheuer; O Sharma
Journal:  Lancet       Date:  1969-05-10       Impact factor: 79.321

7.  Lymphocyte cytotoxicity for isolated hepatocytes in alcoholic liver disease.

Authors:  A M Cochrane; A Moussouros; B Portmann; I G McFarlane; A D Thomson; R Williams
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

8.  Purification and characterization of human liver-specific membrane lipoprotein (LSP).

Authors:  I G McFarlane; B M Wojcicka; G M Zucker; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

9.  Immunological studies in patients with chronic active hepatitis. Cytotoxic activity of lymphocytes to autochthonous liver cells grown in tissue culture.

Authors:  F Paronetto; S Vernace
Journal:  Clin Exp Immunol       Date:  1975-01       Impact factor: 4.330

10.  Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis.

Authors:  J Miller; M G Smith; C G Mitchell; W D Reed; A L Eddleston; R Williams
Journal:  Lancet       Date:  1972-08-12       Impact factor: 79.321

View more
  11 in total

1.  Synthesis and biological evaluation of nitric oxide-releasing derivatives of oleanolic acid as inhibitors of HepG2 cell apoptosis.

Authors:  Li Chen; Yihua Zhang; Xiangwen Kong; Sixun Peng; Jide Tian
Journal:  Bioorg Med Chem Lett       Date:  2007-03-25       Impact factor: 2.823

Review 2.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.

Authors:  Masaya Saito; Yasushi Seo; Yoshihiko Yano; Akira Miki; Masaru Yoshida; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2012-03-24       Impact factor: 7.527

4.  Lymphocyte cytotoxicity for autologous hepatocytes.

Authors:  M Mondelli; A L Eddleston
Journal:  Gut       Date:  1984-02       Impact factor: 23.059

5.  Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis (CAH).

Authors:  L S Si; T L Whiteside; R R Schade; D H Van Thiel
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

Review 6.  Immunologic effector mechanisms in hepatitis B-negative chronic active hepatitis.

Authors:  R J Klingenstein; J R Wands
Journal:  Springer Semin Immunopathol       Date:  1980-12

7.  Lymphocyte transformation test with rabbit liver specific lipoprotein (RLSP) in chronic active hepatitis.

Authors:  L Ortona; V Laghi; R Cauda; P Nervo
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

8.  A quantitative ultrastructural analysis of the leukocytes in contact with hepatocytes in chronic active hepatitis, with a cytochemical detection of mononuclear phagocytes.

Authors:  D Bernuau; E Rogier; G Feldmann
Journal:  Am J Pathol       Date:  1982-12       Impact factor: 4.307

9.  Antiurolithic activity of Origanum vulgare is mediated through multiple pathways.

Authors:  Aslam Khan; Samra Bashir; Saeed R Khan; Anwar H Gilani
Journal:  BMC Complement Altern Med       Date:  2011-10-17       Impact factor: 3.659

10.  Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity.

Authors:  Alexandre Pellan Cheng; Matthew Pellan Cheng; Wei Gu; Joan Sesing Lenz; Elaine Hsu; Erwin Schurr; Guillaume Bourque; Mathieu Bourgey; Jerome Ritz; Francisco Marty; Charles Y Chiu; Donald Cuong Vinh; Iwijn De Vlaminck
Journal:  medRxiv       Date:  2020-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.